Difficulty recruiting patients in US Low volunteer rate, <5% even for cancer trials Liability Mistrust of pharma Less risk-tolerant patients More competition for pts as more drugs in development restrictive inclusion-exclusion req req for larger trials HIPAA Problems in US Trials
{}